FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380080865> ?p ?o ?g. }

• W4380080865 endingPage "416" @default.
• W4380080865 startingPage "414" @default.
• W4380080865 abstract "Introduction: The safety profiles of novel agents are mainly based on clinician-reported adverse events (AEs) from clinical trials. Patient-reported outcomes (PROs) may better represent the treatment burden experienced by patients (pts) compared with clinician-reported AEs. Using data from POLARIX, a double-blind, placebo-controlled, randomized Phase 3 international study (NCT03274492), we previously presented PRO and clinician-reported data showing similar rates of neuropathy (Trněný et al., 2022). Here, we evaluate the reporting of other common symptoms using PRO and clinician-reported data in POLARIX. Methods: POLARIX methods were previously described (Tilly et al., 2022); this analysis included all pts with PRO data. PRO and clinician-reported data described the incidence and severity of fatigue, constipation, diarrhea, nausea, and vomiting. Clinician-reported severity grading was based on the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0. PROs were collected using the European Organisation Research and Treatment of Cancer Quality of Life-Core 30 questionnaire (EORTC QLQ-C30), which was administered to pts at clinic visits on Day 1 of Cycles 1 (baseline), 2, 3, and 5, and end of treatment (EOT). PRO severity scores included ‘A little’, ‘Quite a bit’, and ‘Very much’. Results: Overall, 825 pts were evaluable. From baseline to EOT, PROs showed a higher incidence of symptoms compared with clinicians for fatigue (98% vs. 27%), constipation (68% vs. 29%), diarrhea (56% vs. 26%), nausea (58% vs. 40%), and vomiting (24% vs. 15%). PRO severity scores of ‘Quite a bit’ or ‘Very much’ were reported in 33% of pts for fatigue, 29% for constipation, 17% for diarrhea, 19% for nausea, and 7% for vomiting (Table). Clinicians reported Grade ≥2 symptoms in 11% of pts for fatigue, 11% for constipation, 11% for diarrhea, 14% for nausea, and 6% for vomiting (Table). Conclusions: In POLARIX, pts reported a higher incidence and severity of symptoms compared with clinicians. Although distinct scales were used, the differences in symptom rates reported by pts and clinicians were clinically meaningful. These data may have implications for symptom management, including physician evaluation and communication of symptom expectations for pts. Reporting of symptoms by PROs should be incorporated into clinical trials as an adjunct to standard AE reporting to better characterize the patient experience. Table: Encore Abstract - previously submitted to ASCO 2023 The research was funded by: The POLARIX study (NCT03274492) was sponsored by F. Hoffmann-La Roche Ltd. and Genentech, Inc. Third-party editorial assistance, under the direction of the authors, was provided by Leen Al-Mohammad, BSc, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd. Keywords: Aggressive B-cell non-Hodgkin lymphoma, Combination Therapies Conflicts of interests pertinent to the abstract. N. Mehta-Shah Consultant or advisory role: Kyowa Kirin, Daiichi Sankyo/UCB Japan, Secura Bio, AstraZeneca, F. Hoffmann-La Roche Ltd./Genentech, Inc., Karyopharm Therapeutics, C4 Therapeutics, Ono Pharmaceutical, Kyowa Kirin International Research funding: Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd./Genentech, Inc., Celgene, Verastem, Innate Pharma, Corvus Pharmaceuticals, AstraZeneca, C4 Therapeutics, Daiichi Sankyo, Yingli Pharma, Dizal Pharma C. Flowers Consultant or advisory role: Bayer, Gilead Sciences, Spectrum Pharmaceuticals, AbbVie, Celgene, Denovo Biopharma, BeiGene, Karyopharm Therapeutics, Pharmacyclics/Janssen, F. Hoffmann-La Roche Ltd./Genentech, Inc., Epizyme, Genmab, Seattle Genetics, Foresight Diagnostics, Bristol-Myers Squibb/Celgene, Curio Science, AstraZeneca, MorphoSys Stock ownership: Foresight Diagnostics, N Power Research funding: Acerta Pharma, Janssen Oncology, Gilead Sciences, Celgene, TG Therapeutics, F. Hoffmann-La Roche Ltd./Genentech, Inc., Pharmacyclics, AbbVie, Millennium, Alimera Sciences, Xencor, 4D Pharma, Adaptimmune, Amgen, Bayer, Cellectis, EMD Serono, Guardant Health, Iovance Biotherapeutics, Kite/Gilead, MorphoSys, Nektar, Novartis, Pfizer, Sanofi, Takeda, ZIOPHARM Oncology G. Salles Consultant or advisory role: F. Hoffmann-La Roche Ltd./Genentech, Inc., Janssen, Novartis, MorphoSys, Epizyme, Genmab, Debiopharm Group, Velosbio, Bristol-Myers Squibb, BeiGene, Incyte, Miltenyi Biotec, Ipsen, AbbVie, Kite/Gilead, Loxo/Lilly, Molecular Partners, Nordic Nanovector, RAPT Therapeutics, Takeda, Incyte Stock ownership: Owkin Honoraria: AbbVie, Bayer, Regeneron, Incyte H. Tilly Consultant or advisory role: F. Hoffmann-La Roche Ltd., Incyte, Celgene/Bristol-Myers Squibb Honoraria: Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. Research funding: F. Hoffmann-La Roche Ltd./Genentech, Inc. Educational grants: F. Hoffmann-La Roche Ltd., Janssen N. Chua Consultant or advisory role: Bayer, Amgen, Merck, F. Hoffmann-La Roche Ltd. Canada, Seattle Genetics, Incyte Honoraria: AbbVie Research funding: F. Hoffmann-La Roche Ltd./Genentech, Inc. R. Casasnovas Consultant or advisory role: F. Hoffmann-La Roche Ltd./Genentech, Inc., Takeda, Gilead Sciences, Bristol-Myers Squibb, Merck, AbbVie, Celgene, Janssen, Incyte, ADC Therapeutics Honoraria: F. Hoffmann-La Roche Ltd./Genentech, Inc., Takeda, Gilead Sciences, Bristol-Myers Squibb, Merck, AbbVie, Celgene, Janssen, Amgen Research funding: F. Hoffmann-La Roche Ltd./Genentech, Inc., Gilead Sciences, Takeda Educational grants: F. Hoffmann-La Roche Ltd./Genentech, Inc., Takeda, Gilead Sciences, Janssen, AbbVie F. Miall Consultant or advisory role: F. Hoffmann-La Roche Ltd., Takeda Honoraria: Takeda Other remuneration: F. Hoffmann-La Roche Ltd., Takeda (Speaker’s Bureau) T. M. Kim Consultant or advisory role: AstraZeneca/MedImmune, Janssen Oncology, Novartis, Takeda, Yuhan, Regeneron, Samsung Bioepis Research funding: AstraZeneca Other remuneration: Takeda, Janssen Research & Development, IMBDx, Inc. (Speakers' Bureau) C. Tsai Consultant or advisory role: Novartis, F. Hoffmann-La Roche Ltd., Astellas Pharma, Pfizer Stock ownership: AbbVie, Amgen, BeiGene Honoraria: Astellas Pharma, Bristol-Myers Squibb, BeiGene, Chugai, Harvester, Janssen, Kirin Pharmaceuticals, Novartis, Pfizer Research funding: Astellas Pharma, Bristol-Myers Squibb Other remuneration: Astellas Pharma, Bristol-Myers Squibb, Harvester, Janssen, Kirin Pharmaceuticals, Novartis, Pfizer, Amgen Astellas BioPharma (Speaker’s Bureau) S. Nasta Consultant or advisory role: Merck, MorphoSys, Incyte Honoraria: Acrotech Biopharma Research funding: Millennium, Incyte, Aileron Therapeutics, Debiopharm Group, F. Hoffmann-La Roche Ltd./Genentech, Inc., Atara Biotherapeutics, Rafael Pharmaceuticals, Forty Seven, Pharmacyclics/Janssen V. Craine Employment or leadership position: F. Hoffmann-La Roche Ltd. A. Campinha-Bacote Employment or leadership position: Genentech, Inc. Stock ownership: Genentech, Inc. J. Hirata Employment or leadership position: Genentech, Inc. Stock ownership: F. Hoffmann-La Roche Ltd. C. Lee Employment or leadership position: F. Hoffmann-La Roche Ltd. Stock ownership: F. Hoffmann-La Roche Ltd. M. Sugidono Employment or leadership position: Genentech, Inc./F. Hoffmann-La Roche Ltd. Stock ownership: Genentech, Inc./F. Hoffmann-La Roche Ltd." @default.
• W4380080865 created "2023-06-10" @default.
• W4380080865 creator A5003078312 @default.
• W4380080865 creator A5005349514 @default.
• W4380080865 creator A5010035183 @default.
• W4380080865 creator A5012158679 @default.
• W4380080865 creator A5016764336 @default.
• W4380080865 creator A5024819739 @default.
• W4380080865 creator A5029417544 @default.
• W4380080865 creator A5032681068 @default.
• W4380080865 creator A5038526399 @default.
• W4380080865 creator A5045381939 @default.
• W4380080865 creator A5048152755 @default.
• W4380080865 creator A5057714776 @default.
• W4380080865 creator A5061776528 @default.
• W4380080865 creator A5062305482 @default.
• W4380080865 creator A5062633357 @default.
• W4380080865 creator A5063072439 @default.
• W4380080865 creator A5064765139 @default.
• W4380080865 creator A5082892912 @default.
• W4380080865 date "2023-06-01" @default.
• W4380080865 modified "2023-10-17" @default.
• W4380080865 title "Patient‐ versus clinician‐reported symptoms in the POLARIX study" @default.
• W4380080865 doi "https://doi.org/10.1002/hon.3164_305" @default.
• W4380080865 hasPublicationYear "2023" @default.
• W4380080865 type Work @default.
• W4380080865 citedByCount "0" @default.
• W4380080865 crossrefType "journal-article" @default.
• W4380080865 hasAuthorship W4380080865A5003078312 @default.
• W4380080865 hasAuthorship W4380080865A5005349514 @default.
• W4380080865 hasAuthorship W4380080865A5010035183 @default.
• W4380080865 hasAuthorship W4380080865A5012158679 @default.
• W4380080865 hasAuthorship W4380080865A5016764336 @default.
• W4380080865 hasAuthorship W4380080865A5024819739 @default.
• W4380080865 hasAuthorship W4380080865A5029417544 @default.
• W4380080865 hasAuthorship W4380080865A5032681068 @default.
• W4380080865 hasAuthorship W4380080865A5038526399 @default.
• W4380080865 hasAuthorship W4380080865A5045381939 @default.
• W4380080865 hasAuthorship W4380080865A5048152755 @default.
• W4380080865 hasAuthorship W4380080865A5057714776 @default.
• W4380080865 hasAuthorship W4380080865A5061776528 @default.
• W4380080865 hasAuthorship W4380080865A5062305482 @default.
• W4380080865 hasAuthorship W4380080865A5062633357 @default.
• W4380080865 hasAuthorship W4380080865A5063072439 @default.
• W4380080865 hasAuthorship W4380080865A5064765139 @default.
• W4380080865 hasAuthorship W4380080865A5082892912 @default.
• W4380080865 hasBestOaLocation W43800808651 @default.
• W4380080865 hasConcept C120665830 @default.
• W4380080865 hasConcept C121332964 @default.
• W4380080865 hasConcept C126322002 @default.
• W4380080865 hasConcept C142724271 @default.
• W4380080865 hasConcept C159110408 @default.
• W4380080865 hasConcept C1862650 @default.
• W4380080865 hasConcept C197934379 @default.
• W4380080865 hasConcept C199475168 @default.
• W4380080865 hasConcept C204787440 @default.
• W4380080865 hasConcept C27081682 @default.
• W4380080865 hasConcept C2777793932 @default.
• W4380080865 hasConcept C2779802037 @default.
• W4380080865 hasConcept C2779951463 @default.
• W4380080865 hasConcept C2780580376 @default.
• W4380080865 hasConcept C2780852908 @default.
• W4380080865 hasConcept C2781112942 @default.
• W4380080865 hasConcept C535046627 @default.
• W4380080865 hasConcept C57658597 @default.
• W4380080865 hasConcept C61511704 @default.
• W4380080865 hasConcept C71924100 @default.
• W4380080865 hasConceptScore W4380080865C120665830 @default.
• W4380080865 hasConceptScore W4380080865C121332964 @default.
• W4380080865 hasConceptScore W4380080865C126322002 @default.
• W4380080865 hasConceptScore W4380080865C142724271 @default.
• W4380080865 hasConceptScore W4380080865C159110408 @default.
• W4380080865 hasConceptScore W4380080865C1862650 @default.
• W4380080865 hasConceptScore W4380080865C197934379 @default.
• W4380080865 hasConceptScore W4380080865C199475168 @default.
• W4380080865 hasConceptScore W4380080865C204787440 @default.
• W4380080865 hasConceptScore W4380080865C27081682 @default.
• W4380080865 hasConceptScore W4380080865C2777793932 @default.
• W4380080865 hasConceptScore W4380080865C2779802037 @default.
• W4380080865 hasConceptScore W4380080865C2779951463 @default.
• W4380080865 hasConceptScore W4380080865C2780580376 @default.
• W4380080865 hasConceptScore W4380080865C2780852908 @default.
• W4380080865 hasConceptScore W4380080865C2781112942 @default.
• W4380080865 hasConceptScore W4380080865C535046627 @default.
• W4380080865 hasConceptScore W4380080865C57658597 @default.
• W4380080865 hasConceptScore W4380080865C61511704 @default.
• W4380080865 hasConceptScore W4380080865C71924100 @default.
• W4380080865 hasIssue "S2" @default.
• W4380080865 hasLocation W43800808651 @default.
• W4380080865 hasOpenAccess W4380080865 @default.
• W4380080865 hasPrimaryLocation W43800808651 @default.
• W4380080865 hasRelatedWork W2003784265 @default.
• W4380080865 hasRelatedWork W2030949051 @default.
• W4380080865 hasRelatedWork W2041128529 @default.
• W4380080865 hasRelatedWork W2048568348 @default.
• W4380080865 hasRelatedWork W2347684256 @default.
• W4380080865 hasRelatedWork W2371976426 @default.
• W4380080865 hasRelatedWork W2411848747 @default.

• next